secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001493152-23-039517
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Q3 2023 net loss $0.47/share; cash $16M into Q2 2024; Decoy20 all 4 patients stable disease
--------------------------------------------------------------------------------

- Cash and equivalents $16.0M as of Sep 30, 2023, down from $26.4M at Dec 31, 2022; runway into Q2 2024.
- Net loss per share $0.47 for Q3 2023 versus $0.42 year ago; R&D expense $2.2M (up $0.6M YoY).
- Decoy20 Phase 1 first cohort: all four patients maintain stable disease; first patient dosed in second cohort.
- Roger Waltzman, M.D. appointed Chief Medical Officer effective August 7, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223039517/0001493152-23-039517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223039517/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer